Hone B2B2C Employer Channels
Hone Health
Employer channels can turn Hone from an expensive D2C testosterone seller into a bundled health benefit with much cheaper distribution. Hone already sells a recurring care workflow, monthly clinician access, lab monitoring, and add on medications, which makes it easier to fit into company stipends than a one time test. In practice, a tech or finance employer can subsidize the first visit or monthly membership, then employees keep paying for ongoing prescriptions and follow up care.
-
Hone’s model is unusually well suited to B2B2C because the product is sticky. At the end of 2023, most revenue came from a $129 per month consult subscription plus paid medication add ons, and the treatment often requires ongoing dose changes and blood work. That creates longer retention and higher lifetime value than more transactional telehealth categories like ED.
-
The closest analog is not Ro or Hims, it is employer benefit platforms like Maven and Virta. Maven sells fertility and maternity care into employers because benefits help with recruiting and retention, while Virta sells metabolic care by showing cost savings and outcome based pricing. Hone sits between those models, part talent perk, part recurring care program.
-
Performance medicine stipends also match the buyer profile. Function Health shows how affluent consumers already pay cash for optimization focused testing, imaging, and hormone panels. That matters because tech and finance workers are more likely to use employer dollars for proactive health services that insurance rarely covers, then convert into self pay recurring users.
The likely next step is a broader employer facing longevity bundle, where testosterone becomes one module inside a wider menu that includes weight loss, hormone panels, thyroid care, and other optimization services. If that happens, Hone gets a larger contract surface area, steadier top of funnel, and a path from niche TRT vendor to premium employer health platform.